Kesmalea Therapeutics
Mark Fox is an experienced Finance Director who has held various high-level finance positions in companies within the healthcare and pharmaceutical industries. With a background in business studies, Mark has successfully managed finance and operations departments, as well as planning and forecasting functions. Mark currently serves as the Finance Director at Kesmalea Therapeutics, bringing a wealth of expertise in financial management and strategic planning to their role.
This person is not in any teams
Kesmalea Therapeutics
1 followers
Kesmalea is creating a new generation of protein homeostasis modulators, with a unique chemistry platform technology and therapeutic paradigm. Our novel approach allows us to overcome the challenges of existing protein degradation and stabilisation technologies, opening the door to previously unavailable oral therapeutics in areas of high unmet medical need. Protein homeostasis is the system of maintaining the equilibrium of proteins in the human body. This intricate system is in a constant state of change, with the body continuously synthesising and regulating proteins, whilst removing those which are no longer required (or have mutated) through controlled degradation. Small perturbations of the human body’s natural control mechanism that result in an excess or absence of certain proteins can drive the progression of disease. At Kesmalea, we’re aiming to counter this dysregulation with novel treatments which restore balance through effective protein degradation or stabilisation.